Zydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structured as a tender offer followed by a merger, will give Zydus access to Assertio's commercial platform and its approved oncology asset, Rolvedon. This strategic move aims to expand Zydus's footprint in the US specialty oncology market.
RSS News
Economic times
0 thoughts on “Zydus to buy Assertio for $166.4 million”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- Ameesha shares 'Kaho Naa... Pyaar Hai' throwback moment with Hrithik
- 'Marshals' finale explained: Kayce faces a shocking twist
- Song's lyrics of the day by Taylor Swift
- 'Daily assault of fuel loot not over yet': Congress slams Modi govt for fourth hike in 10 days
- Quote of the day by 'Peddi' star Ram Charan
